{"id":534215,"date":"2021-09-02T18:48:09","date_gmt":"2021-09-02T22:48:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/"},"modified":"2021-09-02T18:48:09","modified_gmt":"2021-09-02T22:48:09","slug":"supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/","title":{"rendered":"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCKVILLE, Md., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022.<\/p>\n<p align=\"justify\">In December 2020, Supernus announced positive topline results from a Phase III study of Qelbree in adults for the treatment of attention deficit hyperactivity disorder (ADHD). The results showed that at a daily dose of up to 600mg, the trial met the primary endpoint with robust statistical significance (p=0.0040) compared to placebo in improving the symptoms of ADHD from baseline to end of study as measured by ADHD Investigator Symptom Rating Scale. In addition to meeting the primary efficacy endpoint, the Phase III study met the key secondary efficacy endpoint with statistical significance (p=0.0023) in the change from baseline of the Clinical Global Impression \u2013 Severity of Illness Scale at week 6. The active dose was well tolerated.<\/p>\n<p align=\"justify\">Qelbree was approved in the U.S. in April 2021 for the treatment of ADHD in pediatric patients 6 to 17 years of age.<\/p>\n<p align=\"justify\">Jack Khattar, President and CEO of Supernus, said, \u201cWe look forward to making Qelbree available to adult patients, if approved by the FDA. Approximately 10 million adults in the U.S. have ADHD, and every adult who has ADHD had it as a child. Adults with ADHD often cope with difficulties at school, at work, and in their personal and family lives.\u201d<\/p>\n<p align=\"justify\">Mr. Khattar continued, \u201cWe are currently focused on Qelbree\u2019s launch in the pediatric market and on providing physicians, parents and patients with a new ADHD treatment that is not a controlled substance with proven efficacy and a tolerable safety profile.\u201d<\/p>\n<p align=\"justify\">\n        <strong>IMPORTANT SAFETY INFORMATION<\/strong>\n      <\/p>\n<p align=\"justify\">Qelbree (viloxazine extended-release capsules) may increase suicidal thoughts and actions in some children with ADHD, especially within the first few months of treatment or when the dose\u00a0is changed. Pay close attention to any new or sudden changes in mood, behavior, thoughts, and feelings. Call your child\u2019s doctor right away if there are any new or sudden changes, or if there is development of suicidal thoughts or actions. Qelbree should not be taken by patients that also take\u00a0certain anti-depression medicines, especially those called a monoamine oxidase inhibitor or MAOI, or certain asthma medicines.<\/p>\n<p>Please see full <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mwbQsOovD_NloKsepb1iCV6ZQJM96vrxe_GbyKAwsybX7dvRYU45maZHQTcsnzPjUY1CKBYZrovRP1_IDy1zy_W35QWf4kboLUNQv3cMTz4NpbGB6DXLSFlQhW_CsTuf3rsOtwJvnf3h7IWRRZ4ll1XlISFUXNOPsZUGs2VZh7A=\" rel=\"nofollow noopener\" target=\"_blank\">Prescribing Information<\/a>, including Boxed Warning, for Qelbree.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About Supernus Pharmaceuticals, Inc.<\/strong>\u00a0\u00a0<\/p>\n<p align=\"justify\">Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.<\/p>\n<p align=\"justify\">Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson\u2019s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson\u2019s disease, epilepsy, depression and rare CNS disorders.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0m0PubhBtIl_foVArbGT_x_nTL4fwEPQrBleRKwibp46-C0xPRYqgWqUMvIEfo6ANqjgmYYjyd4ZBmblML2kaw==\" rel=\"nofollow noopener\" target=\"_blank\">www.supernus.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management&#8217;s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company\u2019s ability to sustain and increase its profitability; the Company\u2019s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company\u2019s corporate strategy; the Company\u2019s future financial performance and projected expenditures; the Company\u2019s ability to increase the number of prescriptions written for each of its products; the Company\u2019s ability to increase its net revenue; the Company\u2019s ability to commercialize its products including Qelbree; the Company\u2019s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company\u2019s product research and development activities, including the timing and progress of the Company\u2019s clinical trials, and projected expenditures; the Company\u2019s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company\u2019s product candidates; the Company\u2019s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company\u2019s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company\u2019s product candidates; the accuracy of the Company\u2019s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company\u2019s ability to increase its manufacturing capabilities for its products and product candidates; the Company\u2019s projected markets and growth in markets; the Company\u2019s product formulations and patient needs and potential funding sources; the Company\u2019s staffing needs; and other risk factors set forth from time to time in the Company\u2019s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.<\/p>\n<p align=\"justify\">\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p align=\"justify\">Jack A. Khattar, President and Chief Executive Officer <br \/>Supernus Pharmaceuticals, Inc.<br \/>Tel: (301) 838-2591<\/p>\n<p align=\"justify\">or<\/p>\n<p align=\"justify\">\n        <strong>INVESTOR CONTACT<\/strong><br \/>\n        <br \/>Peter Vozzo<br \/>Westwicke\/ICR<br \/>Office: (443) 213-0505<br \/>Mobile: (443) 377-4767<br \/>Email: peter.vozzo@westwicke.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODBjZmM2YjktYTU4Yy00OTJjLThlNDktNTdkYmMwMmZiNTFhLTEwMjI1MTU=\/tiny\/Supernus-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022. In December 2020, Supernus announced positive topline results from a Phase III study of Qelbree in adults for the treatment of attention deficit hyperactivity disorder (ADHD). The results showed that at a daily dose &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534215","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022. In December 2020, Supernus announced positive topline results from a Phase III study of Qelbree in adults for the treatment of attention deficit hyperactivity disorder (ADHD). The results showed that at a daily dose &hellip; Continue reading &quot;Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T22:48:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA\",\"datePublished\":\"2021-09-02T22:48:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/\"},\"wordCount\":955,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/\",\"name\":\"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=\",\"datePublished\":\"2021-09-02T22:48:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/","og_locale":"en_US","og_type":"article","og_title":"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA - Market Newsdesk","og_description":"ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022. In December 2020, Supernus announced positive topline results from a Phase III study of Qelbree in adults for the treatment of attention deficit hyperactivity disorder (ADHD). The results showed that at a daily dose &hellip; Continue reading \"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T22:48:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA","datePublished":"2021-09-02T22:48:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/"},"wordCount":955,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/","name":"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=","datePublished":"2021-09-02T22:48:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTgzMyM0Mzg3OTEwIzIwMTA5NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Supernus Announces Qelbree\u2122 sNDA for Adult Indication Accepted for Review by FDA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534215"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}